Billets de Michelle Dawson

Billet publié sur Twitter/X le 12/01/2022 04:46

Retour aux billets Billet précédent Billet suivant
Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme
Ouvrir le billet original

Infos sur le lien intégré au billet

Essai clinique

Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS) (2022). A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism. ClinicalTrials.gov. Icahn School of Medicine at Mount Sinai.

Plus d’infos

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS) (2022). A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism. ClinicalTrials.gov. Icahn School of Medicine at Mount Sinai.

Date de publication
19/01/2022
Identifiant
NCT05187377
Auteurs
Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS)
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Icahn School of Medicine at Mount Sinai
Source de métadonnées
clinicaltrials.gov

Résumé

This clinical trial will use growth hormone as a novel treatment for Phelan-McDermid syndrome (PMS) and idiopathic autism. A double-blind, placebo-controlled crossover trial design will be used in 30 children with idiopathic autism and 15 children with PMS to evaluate the the effects of growth hormone on visual evoked potentials (VEPs), socialization, language, and repetitive behaviors. The researchers expect to provide evidence for the feasibility of using VEPs in PMS, and to show support for growth hormone in ameliorating clinical symptoms of ASD.

Ouvrir la source Lien vers la source citée